Sodium Nitroprusside

硝普钠

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameSodium Nitroprusside
Drug Alias Name亚硝基铁氰化钠硝普纳硝普化钠硝普酸钠Nipride +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNatriuretic peptide receptor 1 agonists
TargetsNatriuretic peptide receptor 1
Therapy Area/IndicationsSchizophreniaHealthy AgingHypertension +[6] 
Global Approved IndicationsHypertensionMyocardial InfarctionHeart Failure +[4] 
Approved Indications in ChinaHypertensionHeart Failure
Original Approved Country/TerritoryUnited States
Original Approved Date1974/05/10
Country/TerritoryUnited StatesGermanyBrazil +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHainan Poly Pharm Co LtdChina Resources Double-Crane Pharmaceutical Co Ltd
Inactive CompaniesUniversity of Sao PauloEunice Kennedy Shriver National Institute Of Child Health And Human DevelopmentF. Hoffmann-La Roche Ltd +[5] 
Active IndicationsHypertensionMyocardial InfarctionHeart Failure +[4] 
Inactive IndicationsSchizophreniaHealthy Aging

Other Information

ATC CodeC02DD01
Related LinksWikipediaDrugBankKEGG